New hope for rare cancers: drug combo trial launches
NCT ID NCT04449549
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 6 times
Summary
This study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare cancers like ovarian, anal, or Ewing sarcoma will participate. The trial is currently recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT GRANULOSA CELL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can engineered immune cells tackle childhood sarcoma?